^
Association details:
| Biomarker: | MECOM rearrangement |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | pevonedistat (MLN4924) (NEDD8 activating enzyme inhibitor) + ABBV-167 (Bcl2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
Published date:
07/08/2023
Excerpt:
In the AML cohort, the median age was 74 years (range 61-86 years), and 27 patients (84%) had at least one adverse risk cyto-molecular feature, including 15 (47%) with a TP53 mutation or MECOM rearrangement; seventeen patients (53%) had received prior therapy for a preceding myeloid disorder. The CR/CRi rate was 66% (CR 50%; CRi 16%), and the median overall survival (OS) was 8.1 months...The triplet combination of azacitidine, venetoclax and pevonedistat shows encouraging activity in this very poor-risk population of patients with AML...
Secondary therapy:
azacitidine
DOI:
10.1186/s13045-023-01476-8
Trial ID:
